Module

Genomics-based Prognostic and Predictive Markers: Are They Ready for Prime Time?

Source: Breast Cancer Annual Update 2005

Genomics-based Prognostic and Predictive Markers: Are They Ready for Prime Time?


CME Program Director: Clifford A. Hudis, MD

Faculty:

  • Soonmyung Paik, MD

CME CREDIT INFORMATION

Release Date: 11/09/05

Expiration Date: 11/08/06


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe microassay methods used to identify molecular markers
  • Discuss role of known molecular markers in assessing risk of recurrence
  • Identify challenges in collecting, analyzing, and interpreting data from microassays

Topics covered include:

  • Introduction
  • Utility of Molecular Markers
  • Gene Expression Profiling Methods
  • Interpreting Gene Expression Profiles
  • Development and Validation of OncotypeDx Assay
  • OncotypeDx Assay vs Adjuvant!
  • OncotypeDx Assay as a Predictor for Response to Chemotherapy
  • Clinical Utility of Stanford Microarray Assay
  • Other Available Prognostic Assays
  • Future Direction of Molecular Markers
  • Summary—Implications for Clinical Practice
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.